## Rui Bi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1261327/publications.pdf

Version: 2024-02-01

31	788	16	27
papers	citations	h-index	g-index
32	32	32	1624
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer, 2018, 18, 4.	2.6	85
2	Apparent Diffusion Coefficient (ADC) Value: A Potential Imaging Biomarker That Reflects the Biological Features of Rectal Cancer. PLoS ONE, 2014, 9, e109371.	2.5	81
3	A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer. PLoS ONE, 2016, 11, e0150505.	2.5	54
4	Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. Journal of Gynecologic Oncology, 2017, 28, e77.	2.2	46
5	An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer. PLoS ONE, 2015, 10, e0125131.	2.5	45
6	Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. Journal of Ovarian Research, 2017, 10, 9.	3.0	42
7	BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. Clinical Cancer Research, 2015, 21, 1752-1763.	7.0	40
8	Microcystic stromal tumour of the ovary: frequent mutations of β atenin ( <i><scp>CTNNB</scp>1</i> ) in six cases. Histopathology, 2015, 67, 872-879.	2.9	35
9	Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. OncoTargets and Therapy, 2016, 9, 131.	2.0	34
10	Molecular portrait of breast cancer in <scp>C</scp> hina reveals comprehensive transcriptomic likeness to <scp>C</scp> aucasian breast cancer and low prevalence of luminal A subtype. Cancer Medicine, 2015, 4, 1016-1030.	2.8	31
11	Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecologic Oncology, 2016, 141, 466-470.	1.4	31
12	Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS ONE, 2017, 12, e0170879.	<b>2.</b> 5	29
13	Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Modern Pathology, 2020, 33, 2473-2482.	5 <b>.</b> 5	29
14	Association between DNA damage repair gene somatic mutations and immuneâ€related gene expression in ovarian cancer. Cancer Medicine, 2020, 9, 2190-2200.	2.8	27
15	Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression. Diagnostic Pathology, 2016, 11, 17.	2.0	26
16	Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. Journal of Gynecologic Oncology, 2016, 27, e18.	2.2	24
17	Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large Bâ€cell lymphoma. Journal of Pathology, 2018, 246, 141-153.	4.5	18
18	Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2020, 144, 1097-1107.	2.5	14

#	Article	IF	CITATIONS
19	Malignant ameloblastoma (metastatic ameloblastoma) in the lung: 3 cases of misdiagnosis as primary lung tumor with a unique growth pattern. Diagnostic Pathology, 2015, 10, 123.	2.0	13
20	Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma. Modern Pathology, 2020, 33, 1275-1286.	5.5	12
21	Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma. Diagnostic Pathology, 2021, 16, 12.	2.0	12
22	Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary. Diagnostic Pathology, 2017, 12, 87.	2.0	11
23	ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma. Diagnostic Pathology, 2019, 14, 96.	2.0	11
24	PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro. OncoTargets and Therapy, 2017, Volume 10, 2239-2247.	2.0	8
25	Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Cancer, 2018, 28, 1108-1116.	2.5	8
26	Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions. Journal of Clinical Pathology, 2018, 71, 546-553.	2.0	6
27	Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients. Annals of Translational Medicine, 2021, 9, 453-453.	1.7	5
28	Pure primary yolk sac tumor of the endometrium tends to occur at a younger age: A case report and literature analysis. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110277.	0.3	3
29	Clinicopathological significance of WT1 expression in invasive breast carcinoma with >90% mucinous component. Journal of Clinical Pathology, 2021, , jclinpath-2021-207464.	2.0	2
30	Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas. American Journal of Surgical Pathology, 2022, 46, 713-724.	3.7	2
31	Abstract P2-13-11: Response to anti-HER2 neoadjuvant chemotherapy in invasive breast cancers with different HER2 FISH-positive patterns. Cancer Research, 2022, 82, P2-13-11-P2-13-11.	0.9	1